Clover Biopharmaceuticals, Ltd, a global biotechnology company with commercial-stage operations and a focus on developing innovative vaccines to protect lives and enhance public health worldwide, has announced the completion of first-participant enrollment in a Phase 2 clinical study in Australia.
The trial is evaluating two protein-based vaccine candidates: SCB-1022, targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and SCB-1033, which targets RSV, hMPV, and parainfluenza virus type 3 (PIV3). Both candidates are built on prefusion-stabilized F (PreF) Trimer subunit antigens using Clover’s proprietary and validated Trimer-Tag vaccine technology platform.
Joshua Liang, Chief Executive Officer and Board Director of Clover, stated that the launch of this Phase 2 study represents a significant advancement for the company’s respiratory combination vaccine program.
He noted that the trial reinforces Clover’s ambition to deliver first-in-class vaccine solutions and follows encouraging Phase 1 results that suggest these RSV+hMPV±PIV3 combinations may offer best-in-class potential. According to Liang, the candidates may also enable revaccination in individuals who have previously received approved RSV vaccines, helping to restore and expand protection while addressing substantial unmet global health needs.
The Phase 2 study is a randomized, observer-blinded, multi-center trial being conducted across Australia and is expected to enroll up to 420 adults aged 60 to 85 years. Participants will be randomly assigned to receive SCB-1022, SCB-1033, or a placebo. The primary objectives of the trial include evaluating the safety profile, reactogenicity, and immunogenicity of the vaccine candidates.
The trial is evaluating two protein-based vaccine candidates: SCB-1022, targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and SCB-1033, which targets RSV, hMPV, and parainfluenza virus type 3 (PIV3). Both candidates are built on prefusion-stabilized F (PreF) Trimer subunit antigens using Clover’s proprietary and validated Trimer-Tag vaccine technology platform.
Joshua Liang, Chief Executive Officer and Board Director of Clover, stated that the launch of this Phase 2 study represents a significant advancement for the company’s respiratory combination vaccine program.
He noted that the trial reinforces Clover’s ambition to deliver first-in-class vaccine solutions and follows encouraging Phase 1 results that suggest these RSV+hMPV±PIV3 combinations may offer best-in-class potential. According to Liang, the candidates may also enable revaccination in individuals who have previously received approved RSV vaccines, helping to restore and expand protection while addressing substantial unmet global health needs.
The Phase 2 study is a randomized, observer-blinded, multi-center trial being conducted across Australia and is expected to enroll up to 420 adults aged 60 to 85 years. Participants will be randomly assigned to receive SCB-1022, SCB-1033, or a placebo. The primary objectives of the trial include evaluating the safety profile, reactogenicity, and immunogenicity of the vaccine candidates.